Research context (RUO): Melanotan 2 and PT-141 (bremelanotide) are cyclic melanocortin analogues. Both peptides are supplied by Peplife exclusively for in vitro laboratory research (Research Use Only) and are not intended for human or animal use.
Melanotan 2 vs PT-141: the difference explained
The comparison melanotan 2 vs PT-141 concerns two peptides that sit so close together that one arises from the other inside the body. PT-141, whose generic name is bremelanotide, is the principal active metabolite of melanotan 2. Yet one of them is approved nowhere in the world and the other is, and their research domains differ fundamentally. The chemical distinction is minimal: an amide group versus a free acid at the end of the ring. This pillar explains how that single group shifts the receptor profile, and with it the entire research field.
The core: PT-141 is the metabolite of melanotan 2
Melanotan 2 is a cyclic heptapeptide derived from melanocyte-stimulating hormone. In the body it is converted, among other routes, through loss of the terminal amide group, which yields bremelanotide. In animal research that metabolite proved responsible for part of the observed effects that had nothing to do with pigment, and it was subsequently taken up as a research candidate in its own right. Historically, then, PT-141 is not a competitor of melanotan 2 but an offshoot of it.
One single chemical difference: amide versus free acid
Both molecules share the same ring structure and the same seven building blocks. Melanotan 2 carries an amide group at the end of the chain; in PT-141 that group is replaced by a free carboxylic acid group. This looks marginal, but the charge at that end determines how tightly the molecule fits into the binding pocket of each melanocortin receptor subtype. It is precisely at MC1R, the receptor that drives pigment formation, that affinity falls off noticeably, while binding to MC3R and MC4R is largely retained.
Receptor profile: pigment versus central signalling
Melanotan 2 is a broad, non-selective agonist: it addresses MC1R, MC3R, MC4R and MC5R. As a result, the pigment response comes along in virtually every model in which it is studied, regardless of what is actually being measured. PT-141 shifts the centre of gravity to MC3R and MC4R in the central nervous system. That makes it usable in models of central melanocortin signalling without the pigment pathway as a confounding variable. The 2022 work by Thurston and colleagues brought that central processing under MC4R agonism into view.
The two analogues side by side
| Feature | Melanotan 2 | PT-141 (bremelanotide) |
|---|---|---|
| Relationship | Parent molecule | Active metabolite |
| C-terminus | Amide group | Free carboxylic acid group |
| Receptor profile | Broad: MC1R through MC5R | Focus on MC3R and MC4R |
| Pigment response in models | Markedly present | Strongly reduced |
| Research domain | Pigmentation and melanocortin biology | Central melanocortin signalling |
| Regulatory status | Approved nowhere | Approved in the United States, 2019 |
| Route in studies | Subcutaneous | Subcutaneous, previously intranasal |
Regulatory status: approved versus approved nowhere
This is the sharpest distinction between the two substances. Bremelanotide went through a full clinical programme and was approved in the United States in 2019 as a registered medicine, administered with a subcutaneous auto-injector. Melanotan 2 never followed that path and is registered as a medicine nowhere in the world; regulators in several EU countries have in fact explicitly warned against it. For reading the literature that means: around PT-141 there is controlled human data, around melanotan 2 almost exclusively preclinical work and case reports.
Why the route of administration in studies changed
The early human studies with bremelanotide used a nasal spray. That route was abandoned after rises in blood pressure were observed in the programme, after which development moved to subcutaneous administration at a lower dose. It is a detail that is often skipped over when reading older publications. Outcomes from the intranasal phase cannot simply be compared with the later subcutaneous programme, because both the route and the dosing differ.
What this means for the choice within a research model
Anyone who wants to study the melanocortin receptor family across its full breadth, including the pigment pathway, has the broader instrument in melanotan 2. Anyone who wants to isolate central signalling instead reaches for PT-141, so that the MC1R response does not cloud the outcome. A third option is melanotan 1, which has exactly the opposite selectivity and addresses almost exclusively MC1R. Together those three form a workable spectrum for pulling receptor contributions apart; the pillar Melanotan 1 vs melanotan 2 covers the other side of that spectrum.
Both analogues in laboratory research: handling and dissolving
Both are cyclic peptides and therefore more stable than their linear counterparts, yet they remain light-sensitive. As a lyophilised powder they keep for a long time at minus twenty degrees Celsius; after reconstitution with bacteriostatic water they belong in refrigerated, dark storage. Because the difference between the two molecules is literally one functional group, it is all the more important not to mix up or relabel vials. The reconstitution guide sets out the calculation steps and the practicalities of preparation and storage.
Quality & purity
An amide and a free acid differ by roughly one mass unit. Only sound mass spectrometry and HPLC show which of the two is actually in the vial. Incomplete amidation during synthesis produces exactly this mix-up. Every relevant batch is independently HPLC-tested by an external laboratory and the certificate of analysis is publicly verifiable per batch. In the pillar why we rejected a batch you can read how that process works in practice.
Frequently asked questions about melanotan 2 and PT-141
Is PT-141 the same as melanotan 2?
No, but they are closely related: PT-141 is the active metabolite of melanotan 2, carrying a free carboxylic acid group where melanotan 2 has an amide group.
Why does PT-141 give far less pigment response?
Because of that altered end group, affinity for MC1R, the receptor behind pigment formation, falls off sharply, while MC3R and MC4R are largely retained.
Which of the two is approved as a medicine?
Bremelanotide, the generic name of PT-141, was approved in the United States in 2019. Melanotan 2 is registered nowhere in the world.
Why did research move from nasal spray to injection?
Rises in blood pressure were observed in the intranasal programme, after which development continued with subcutaneous administration at a lower dose.
Which peptide suits research into pigmentation?
For the pigment pathway itself, melanotan 1 is the most selective instrument and melanotan 2 the broadest; PT-141 is precisely the wrong tool for it.
Read more & research at Peplife
- Research Melanotan 2 at Peplife
- Research PT-141 at Peplife
- Research Melanotan 1 at Peplife
- View all skin peptides
- Melanotan 2: research into the non-selective analogue
- PT-141, kisspeptin and oxytocin compared
- Melanotan 1 vs melanotan 2
- Skin and tanning peptides: the overview
Sources: Thurston et al., MC4R agonism and sexual brain processing, J Clin Invest 2022 · PubChem CID 92432 — Melanotan-II · DermNet — Melanotan II · Melanotan II — overview
Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.
Both melanocortin analogues are HPLC-tested by an external laboratory, with a per-batch verifiable CoA and discreet EU shipping.